Evidence map›Paper›PMID 41367488›Full record

ArticleInfectious Disease Modelling2026

A compartmental model of variant coexistence, dynamics and dominance in infectious diseases: Case for SARS-CoV-2 in Abu Dhabi.

Mauricio Patón, Mireille Hantouche, Farida Al-Hosani, Amrit Sadani, Jorge Rodríguez, Rowan Abuyadek

Abstract read
In one paragraph

Article in Infectious Disease Modelling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mauricio PatónBiotechnology Center, Khalifa University, PO Box 127788, Abu Dhabi, United Arab Emirates.
Mireille HantoucheDepartment of Public Health and Epidemiology, Khalifa University, PO Box 127788, Abu Dhabi, United Arab Emirates.
Farida Al-HosaniGlobal Institute for Disease Elimination (GLIDE), Abu Dhabi, United Arab Emirates.
Amrit SadaniDepartment of Health, Abu Dhabi, United Arab Emirates.
Jorge RodríguezDepartment of Chemical Engineering. Khalifa University, PO Box 127788, Abu Dhabi, United Arab Emirates.
Rowan AbuyadekAbu Dhabi Public Health Centre, Abu Dhabi, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the rapid mutation of SARS-CoV-2 has led to the emergence of new variants. Despite advancements in pandemic control, these new variants could pose substantial public health issues. This study introduces a comprehensive compartmental model that can handle multiple virus variants and population groups. The model also factors the influence of international visitors, per variant and group, on the population, which is pertinent for populations with a high ratio of incoming travellers. The model was applied to simulate the coexistence of different variants in the Emirate of Abu Dhabi from August 2022 until March 2023. Calibration was conducted using the data available from Abu Dhabi health authorities and international data from GISAID to estimate the prevalence of each variant. The model seems to effectively depict the temporal coexistence of multiple strains and, ultimately, the rise of a dominant variant. The simulation results from Abu Dhabi indicate that the XBB variant became the dominant strain by the end of the simulation period. The calibrated parameters for the XBB variant suggest that its dominance can be attributed to its superior ability to evade immunity and its increased infectiousness, estimated to be approximately 15 % more than the BQ.1 variant. The introduction of the XBB variant through infected visitors further amplified its emergence.

Identifiers

PMID41367488
PMCPMC12684899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.